Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EDAP logo EDAP
Upturn stock ratingUpturn stock rating
EDAP logo

EDAP TMS SA (EDAP)

Upturn stock ratingUpturn stock rating
$1.65
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: EDAP (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $5.75

1 Year Target Price $5.75

Analysts Price Target For last 52 week
$5.75Target price
Low$1.26
Current$1.65
high$5.28

Analysis of Past Performance

Type Stock
Historic Profit -27.62%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 62.44M USD
Price to earnings Ratio -
1Y Target Price 5.75
Price to earnings Ratio -
1Y Target Price 5.75
Volume (30-day avg) 3
Beta 0.02
52 Weeks Range 1.26 - 5.28
Updated Date 06/30/2025
52 Weeks Range 1.26 - 5.28
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.68

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -34.33%
Operating Margin (TTM) -44.22%

Management Effectiveness

Return on Assets (TTM) -16.54%
Return on Equity (TTM) -49.28%

Valuation

Trailing PE -
Forward PE 38.02
Enterprise Value 45998703
Price to Sales(TTM) 0.99
Enterprise Value 45998703
Price to Sales(TTM) 0.99
Enterprise Value to Revenue 0.63
Enterprise Value to EBITDA 1165.78
Shares Outstanding 37392100
Shares Floating 29010276
Shares Outstanding 37392100
Shares Floating 29010276
Percent Insiders -
Percent Institutions 41.38

Analyst Ratings

Rating 2
Target Price 5.75
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold 2
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

EDAP TMS SA

stock logo

Company Overview

overview logo History and Background

EDAP TMS SA was founded in 1979 and is headquartered in Vaulx-en-Velin, France. It develops, manufactures, and markets minimally invasive medical devices for urology using focused ultrasound and laser technologies. The company has evolved from pioneering extracorporeal shockwave lithotripsy to high-intensity focused ultrasound (HIFU) for prostate cancer treatment.

business area logo Core Business Areas

  • HIFU: Develops and markets High-Intensity Focused Ultrasound (HIFU) devices, primarily the Ablatherm and Focal One systems, for the treatment of localized prostate cancer and other urological conditions.
  • Urology Devices: Develops and markets devices for urological indications using laser technologies. Products include laser fibers and accessories.
  • Distribution of Consumables: Distribution of consumables that are used in conjunction with EDAP systems.

leadership logo Leadership and Structure

Marc Oczachowski serves as the Chief Executive Officer. The company has a board of directors with expertise in medical technology and finance.

Top Products and Market Share

overview logo Key Offerings

  • Focal One: Focal One is a HIFU system for focal therapy of prostate cancer. It allows precise ablation of targeted areas within the prostate. Market share is estimated at around 25% in the HIFU market for prostate cancer treatment. Competitors include Profound Medical (PROF) and Sonacare Medical.
  • Ablatherm: Ablatherm Integrated Imaging is a HIFU system used for whole gland ablation of the prostate. Market share is significant but decreasing as focal therapy gains traction. Competitors include Profound Medical (PROF) and Sonacare Medical.
  • Laser Fibers: EDAP also supplies laser fibers for the treatment of urinary conditions such as Benign Prostatic Hyperplasia (BPH). Competitors include Boston Scientific (BSX), Lumenis, and Olympus

Market Dynamics

industry overview logo Industry Overview

The market for minimally invasive urological treatments is growing, driven by an aging population, increasing incidence of prostate cancer, and patient preference for less invasive procedures. Technologies like HIFU and laser ablation are gaining acceptance.

Positioning

EDAP TMS SA is a leader in HIFU technology for prostate cancer treatment, with a strong reputation for innovation and clinical expertise. They face competition from other HIFU and alternative treatment providers.

Total Addressable Market (TAM)

The total addressable market for prostate cancer treatment is estimated to be in the billions of dollars annually. EDAP is positioning itself to capture a significant portion of this market through its HIFU technology, particularly with the rise of focal therapy. EDAP has a revenue less than $100M USD and based on competitors, they may be able to growth several-fold into this TAM.

Upturn SWOT Analysis

Strengths

  • Pioneering HIFU technology
  • Established brand recognition
  • Extensive clinical data supporting HIFU efficacy
  • Experienced leadership team

Weaknesses

  • Limited market penetration compared to established surgical options
  • Reliance on specific urological procedures
  • Relatively small size compared to major medical device companies
  • Geographic concentration of revenue

Opportunities

  • Expanding applications of HIFU technology
  • Increasing adoption of focal therapy for prostate cancer
  • Geographic expansion into new markets
  • Strategic partnerships with hospitals and urology practices

Threats

  • Competition from established surgical techniques
  • Emergence of new minimally invasive technologies
  • Reimbursement challenges for HIFU procedures
  • Economic downturn affecting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • PROF
  • BSX
  • LMNR

Competitive Landscape

EDAP TMS SA possesses a strong hold within the HIFU space but faces competition from larger medical device companies with broader portfolios. EDAP needs to maintain its technological advantage and marketing efforts to remain competitive.

Growth Trajectory and Initiatives

Historical Growth: EDAP TMS SA's growth has been driven by the adoption of HIFU technology for prostate cancer treatment. Growth is dependent on acceptance in the medical community.

Future Projections: Analysts project continued growth for EDAP TMS SA, driven by increased adoption of HIFU and expansion into new markets. Actual future growth can vary.

Recent Initiatives: Focus on expanding focal therapy capabilities with Focal One, entering new geographic markets, and increasing sales and marketing efforts.

Summary

EDAP TMS SA is a specialized company in the minimally invasive medical device space, specifically focused on HIFU technology for urology. Its Focal One system is gaining traction, indicating growth potential. The company faces competition from larger, more established players and relies heavily on the urology market for revenue. Reimbursement rates, and expanding into new markets will be key to sustainable success. Continued technological advancement in the HIFU space is critical to keep its first mover advantage.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • Press Releases
  • Analyst Reports
  • Market Research Reports

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Market share estimates are based on available data and may not be precise. Investment decisions should be based on thorough research and consultation with a financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About EDAP TMS SA

Exchange NASDAQ
Headquaters -
IPO Launch date 1997-07-31
CEO & Director Mr. Ryan Rhodes
Sector Healthcare
Industry Medical Distribution
Full time employees 310
Full time employees 310

EDAP TMS S.A., together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL segment manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters. This segment also sells spare parts and disposables, such as electrodes. The DIST segment markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing and sales channels, as well as through third-party distributors and agents. The company serves academic, public, and private hospitals as well as urology clinics. EDAP TMS S.A. was incorporated in 1979 and is based in Vaulx-en-Velin, France.